Clinical Trials Logo
  1. Home
  2. Glaucoma
  3. NCT00481494
  4. Details
NCT00481494 Clinical Trial

Personality Characteristics and Compliance With Antiglaucoma Medication

Glaucoma Clinical Trial

— GDC  

Official title:
Personality Characteristics and Compliance With Antiglaucoma Medication

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT00481494
Other study ID # 4-2007-0092
Secondary ID
Status Recruiting
Phase N/A
First received May 31, 2007
Last updated May 31, 2007
Start date May 2007
Est. completion date October 2007

Study information
Verified date May 2007
Source Yonsei University
Contact Chan Yun Kim, MD, PhD
Phone 82-2-2228-3580
Email kcyeye@yumc.yonsei.ac.kr
Is FDA regulated No
Health authority Republic of Korea: Institutional Review Board
Study type Observational

Clinical Trial Summary

Personality traits may influence to the drug compliance in glaucoma patients.

Description:

In chronic diseases, especially asymptomatic at early stage, drug compliance has been reported as an important factor to control them. And personality traits are associated with the drug compliance. However, there was few study to consider this relationship. We want to find the association the personality characteristics and drug compliance in glaucoma patients.

Recruitment information / eligibility
Status Recruiting
Enrollment 150
Est. completion date October 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Chronic glaucoma

- Topical anti-glaucoma medications

Exclusion Criteria:

- Oral glaucoma medications

Study Design

Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Severance Hospital, Yonsei University College of Medicine Seoul

Sponsors (1)
Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A